BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $58 to $10.
BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $58 to $10.